Argenx Se (ARGX) Accounts Payables (2015 - 2026)
Argenx Se (ARGX) posted quarterly Accounts Payables of $1.5 billion for Q2 2026, down 99.85% year-on-year from $1016.2 billion in Q2 2025, and up 19.57% on a QoQ basis from $1.3 billion in Q4 2025.
Argenx Se (ARGX) Accounts Payables (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Accounts Payables for 12 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.
- Quarterly Accounts Payables fell 99.85% year-over-year to $1.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.5 billion (down 99.85% YoY) and the FY2025 annual result came in at $1.3 billion, up 94.93% from the prior year.
- Accounts Payables grew to $1.5 billion in Q2 2026 per ARGX's latest filing, from $1.3 billion in the prior quarter.
- Over the last five years, Accounts Payables for ARGX reached as high as $1016.2 billion in Q2 2025 and fell as low as $257.7 million in Q2 2022.
- A 5-year average of $113.5 billion and a median of $479.8 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2025 — Accounts Payables surged 211675.45% — and 2026, when it tumbled 99.85%.
- Year by year, Accounts Payables stood at $295.7 million in 2022, then soared by 40.02% to $414.0 million in 2023, then jumped by 57.0% to $650.0 million in 2024, then soared by 94.93% to $1.3 billion in 2025, then grew by 19.57% to $1.5 billion in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.5 billion, $1.3 billion, and $1016.2 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 126.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.52 Bn |
| Dec 31, 2025 | 1.27 Bn |
| Jun 30, 2025 | 1,016.16 Bn |
| Dec 31, 2024 | 649.99 Mn |
| Jun 30, 2024 | 479.83 Mn |
| Dec 31, 2023 | 414.01 Mn |
| Jun 30, 2023 | 309.99 Mn |
| Dec 31, 2022 | 295.68 Mn |
| Jun 30, 2022 | 257.69 Mn |
| Dec 31, 2021 | 293.42 Mn |
| Jun 30, 2021 | 239.44 Mn |
| Dec 31, 2020 | 255.20 Mn |
| Jun 30, 2020 | 145.49 Mn |
| Dec 31, 2019 | 97.07 Mn |
| Jun 30, 2019 | 62.66 Mn |
| Dec 31, 2018 | 42.19 Mn |
| Jun 30, 2018 | 31.11 Mn |
| Dec 31, 2017 | 22.06 Mn |
| Jun 30, 2017 | 18.86 Mn |
| Dec 31, 2016 | 17.59 Mn |